Skip to main content
Cancer Genetics prices $3M public offering

A public offering of over 13 million shares of common stock has been priced by Cancer Genetics in hopes of raising $3 million in gross proceeds. The company intends to use the proceeds to pay lender fees and other costs related to the potential forbearance deals it is negotiating with banks, and to pay certain costs resulting from the termination of its deal to acquire NovellusDx.

Full Story: